Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia (C.E.M., A.M.P., M.S.S., C.A.R, I.C.F.); School of Science, STEM College, RMIT University, Melbourne, VIC, Australia (A.H.); and School of Biosciences, The University of Melbourne, Parkville, VIC, Australia (A.M.P.).
Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia (C.E.M., A.M.P., M.S.S., C.A.R, I.C.F.); School of Science, STEM College, RMIT University, Melbourne, VIC, Australia (A.H.); and School of Biosciences, The University of Melbourne, Parkville, VIC, Australia (A.M.P.)
Mol Pharmacol. 2023 Aug;104(2):62-72. doi: 10.1124/molpharm.123.000676. Epub 2023 Jun 6.
Org 34167 is a small molecule hyperpolarization-activated cyclic nucleotide-gated (HCN) channel modulator that has been trialed in humans for its potential antidepressant activity. The precise action of Org 34167 is not fully understood. Here we use two-electrode voltage clamp recordings and an allosteric model to explore the interaction of Org 34167 with human HCN1 channels. The impact of Org 34167 on channel function included a hyperpolarizing shift in activation voltage dependence and a slowing of activation kinetics. Furthermore, a reduction in the maximum open probability at extreme hyperpolarization argued for an additional voltage-independent mechanism. Org 34167 had a similar impact on a truncated HCN1 channel lacking the C-terminal nucleotide binding domain, thus ruling out an interaction with this domain. Fitting a gating model, derived from a 10-state allosteric scheme, predicted that Org 34167 strongly reduced the equilibrium constant for the voltage-independent pore domain to favor a closed pore, as well as reducing the voltage sensing domain-pore domain coupling and shifting the zero voltage equilibrium constant of the voltage sensing domain to favor the inactive state. SIGNIFICANCE STATEMENT: The brain penetrant small molecule Org 34167 has been reported to have an antidepressant action by targeting HCN channels; however, its mode of action is unknown. We used heterologously expressed human HCN1 channels to show that Org 34167 inhibits channel activity by modulating kinetic parameters associated with the channel pore domain, voltage sensing domain, and interdomain coupling.
Org 34167 是一种小分子超极化激活环核苷酸门控 (HCN) 通道调节剂,已在人体中进行试验,以评估其潜在的抗抑郁活性。Org 34167 的确切作用尚不完全清楚。在这里,我们使用双电极电压钳记录和变构模型来探索 Org 34167 与人类 HCN1 通道的相互作用。Org 34167 对通道功能的影响包括激活电压依赖性的超极化偏移和激活动力学的减慢。此外,在极端超极化时最大开放概率的降低表明存在额外的与电压无关的机制。Org 34167 对缺乏 C 末端核苷酸结合域的截断 HCN1 通道具有相似的影响,因此排除了与该结构域的相互作用。拟合门控模型,源自 10 态变构方案,预测 Org 34167 强烈降低了与电压无关的孔域的平衡常数,有利于关闭孔,同时降低电压传感域-孔域偶联,并将电压传感域的零电压平衡常数移至有利于非活性状态。重要性声明:脑穿透小分子 Org 34167 已被报道通过靶向 HCN 通道具有抗抑郁作用;然而,其作用机制尚不清楚。我们使用异源表达的人类 HCN1 通道表明,Org 34167 通过调节与通道孔域、电压传感域和域间偶联相关的动力学参数来抑制通道活性。